Navigation Links
Kendle to Present at the Wachovia 2008 Healthcare Conference
Date:1/28/2008

CINCINNATI, Jan. 28 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization, today announced that Chairman and Chief Executive Officer Candace Kendle, PharmD will participate in the Wachovia 2008 Healthcare Conference. The conference will be held at the Langham Hotel in Boston, Jan. 29-31, 2008. Kendle's presentation is scheduled for Wednesday, Jan. 30 at 1:30 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )

The public is invited to listen to a live webcast of Kendle's presentation at http://www.kendle.com (click on the link provided in the Investor Events section) or at http://www.wsw.com/webcast/wa48/kndl. An archived version can be accessed following Kendle's presentation and will be available through Feb. 28. Slides accompanying the presentation will be available by 9 a.m. Eastern Time on Jan. 30 at http://www.kendle.com in the Investor Relations section.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share.

Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
2. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
3. Kendle Invites You to Attend Its Third Quarter 2007 Earnings Conference Call and Webcast
4. Kendle to Present at the Natixis Bleichroeder Hidden Gems Conference
5. Kendle to Present at the UBS Global Life Sciences Conference
6. Kendle to Present at Bear Stearns 20th Annual Healthcare Conference
7. Kendle to Present at Thomas Weisel Partners Healthcare Conference 2007
8. Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event
9. Kendle to Ring Opening Bell at NASDAQ Stock Market on August 22
10. Phytomedics Inc. to Present at Wachovia 2008 Healthcare Conference
11. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A ... offer a new way to treat the disease. Surviving Mesothelioma has just posted an ... Scientists from several Korean institutions based their mesothelioma study on the fact the Manumycin ...
(Date:5/19/2016)... , ... May 19, 2016 , ... Anton Paar USA, ... square foot office building is complete. The new structure adds a third office building ... Anton Paar USA purchased 2.4 acres of land, along with office space adjacent ...
(Date:5/19/2016)... NEW YORK , May 19, 2016 ... Biotech space will fully recover given the relentless pressures ... is for sure in the investors circle though - ... requires due-diligence. Ahead of today,s session, ActiveWallSt.com,s presents four ... PTLA ), Vitae Pharmaceuticals Inc. (NASDAQ: ...
(Date:5/19/2016)... , May 19, 2016 ... and (OTC PINK: RGBPP) announced today initiation of ... first cord blood based cancer immunotherapeutic product leveraging ... application, Regen described a generation of cord blood ... by gene silencing.  The product in development will ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):